Amedisys, Inc. (NASDAQ:AMED) Receives $100.75 Average Price Target from Analysts

Amedisys, Inc. (NASDAQ:AMED) has received an average rating of “Hold” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $100.75.

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th.

Hedge Funds Weigh In On Amedisys

A number of large investors have recently bought and sold shares of the company. Norges Bank bought a new stake in Amedisys in the fourth quarter valued at approximately $83,061,000. Wealthfront Advisers LLC bought a new stake in Amedisys during the fourth quarter worth about $72,970,000. Pentwater Capital Management LP boosted its position in shares of Amedisys by 178.3% during the 4th quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider’s stock worth $107,132,000 after acquiring an additional 756,000 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of Amedisys by 11,621.9% during the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after buying an additional 553,435 shares in the last quarter. Finally, Polar Asset Management Partners Inc. acquired a new position in Amedisys during the third quarter worth about $28,953,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Stock Performance

AMED stock opened at $92.57 on Friday. The company has a 50-day simple moving average of $92.14 and a 200 day simple moving average of $92.78. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $3.04 billion, a P/E ratio of 36.73, a PEG ratio of 1.78 and a beta of 0.76. Amedisys has a fifty-two week low of $82.15 and a fifty-two week high of $98.95.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09). The business had revenue of $598.05 million during the quarter, compared to analyst estimates of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Sell-side analysts predict that Amedisys will post 4.4 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.